Royce & Associates LP Axonics, Inc. Transaction History

Royce & Associates LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$49.38 - $63.75 $444,420 - $573,750	9,000 Added 32.14%	37,000 $2.3 Million
Q2 2023 Aug 07, 2023	SELL	$47.99 - $60.21 $1.44 Million - $1.81 Million	-30,000 Reduced 51.72%	28,000 $1.41 Million
Q1 2023 May 04, 2023	SELL	$52.6 - $67.34 $1.42 Million - $1.82 Million	-27,000 Reduced 31.76%	58,000 $3.16 Million
Q4 2022 May 23, 2023	BUY	$59.56 - $76.6 $1.61 Million - $2.07 Million	27,000 Added 46.55%	85,000 $5.32 Million
Q4 2022 Feb 13, 2023	SELL	$59.56 - $76.6 $238,240 - $306,400	-4,000 Reduced 4.49%	85,000 $5.32 Million
Q2 2022 Aug 04, 2022	BUY	$39.5 - $64.42 $987,500 - $1.61 Million	25,000 Added 39.06%	89,000 $5.04 Million
Q1 2022 May 05, 2022	BUY	$43.74 - $62.76 $393,660 - $564,840	9,000 Added 16.36%	64,000 $4.01 Million
Q4 2021 Feb 07, 2022	BUY	$50.01 - $73.35 $400,080 - $586,800	8,000 Added 17.02%	55,000 $3.08 Million
Q3 2020 Nov 12, 2020	BUY	$35.33 - $51.04 $671,270 - $969,760	19,000 Added 67.86%	47,000 $2.4 Million
Q2 2020 Aug 07, 2020	BUY	$22.91 - $39.83 $641,480 - $1.12 Million	28,000 New	28,000 $983,000

234

42.1M

83.4K

65.3K

Ticker AXNX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 49,123,600
Market Cap $3.49B
Description
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.